Podophyllotoxin derivative VP 16-213.
VP 16-213, a derivative of podophyllotoxin, is currently entering phase-III studies. Its mode of action is incompletely understood, but differs markedly from that of its parent compound. The greatest lethal damage is experienced by cells in the late S and G2 phases. In the L 1210 system the drug shows marked schedule dependency: prolonged administration may be more effective than single bolus administration. As a single agent, VP 16-213 is the most active compound yet tested against small-cell bronchial carcinoma. It may also prove to be a useful agent in patients with other types of lung tumour, testicular teratomas, and some types of leukaemia. No long-term or cumulative toxicity has been reported. Most side effects are predictable and reproducible.
D000818:Animals; D001984:Bronchial Neoplasms / Q000188:drug therapy; D002277:Carcinoma / Q000188:drug therapy; D002986:Clinical Trials as Topic; D004334:Drug Administration Schedule; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D006801:Humans; D066298:In Vitro Techniques; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D051379:Mice; D009369:Neoplasms / Q000188:drug therapy*; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D011817:Rabbits; D051381:Rats; D012509:Sarcoma / Q000188:drug therapy
D005047:Etoposide; D011034:Podophyllotoxin